-
Mashup Score: 0Maintenance PARP Yields Impressive PFS Benefit in Recurrent, Platinum-Sensitive Ovarian Cancer - 4 year(s) ago
Amanda L. Jackson, MD, , discusses the role of PARP inhibitors in the maintenance treatment of patients with recurrent platinum-sensitive ovarian cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The primary end point of the PRIMA study progression-free survival by blinded independent committee review and secondary end points included overall survival and PROs. @BPothuri @nyulangone @myESMO #ESMO20 #gynca https://t.co/L3UVedL4q7
-
-
Mashup Score: 0Dostarlimab Demonstrates Durable Antitumor Activity in Mismatch Repair Proficient/dMMR Endometrial Cancer - 4 year(s) ago
Dostarlimab showcased durable antitumor activity in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer, with a notable disease control rate and a promising safety profile.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dostarlimab showcased durable antitumor activity in patients with advanced or recurrent DNA dMMR and MMRp endometrial cancer, with a notable DCR and a promising safety profile. @VHIO @myESMO #ESMO20 #gynca https://t.co/Q7uXvkioB1
-
-
Mashup Score: 0Dostarlimab Demonstrates Durable Antitumor Activity in Mismatch Repair Proficient/dMMR Endometrial Cancer - 4 year(s) ago
Dostarlimab showcased durable antitumor activity in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer, with a notable disease control rate and a promising safety profile.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ana Oaknin, MD, PhD, of @VHIO, discusses the utility of dostarlimab in advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer. @myESMO #ESMO #gynca https://t.co/WmDvwXXz9K https://t.co/i9iOcrVbq5
-
-
Mashup Score: 0ESMO 2020 News | OncLive - 4 year(s) ago
OncLive serves as a connection to everything oncology, including interviews and videos from thought leaders and cutting edge articles and resources.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
If you missed our #OncLiveOnLocation at #ESMO20, have no fear! We have the whole series available for viewing. Relive the biggest data in gynecologic malignancies with @rcoledude, of @TheUSONetwork. https://t.co/wcnlCvjGhW @myESMO @ginacolumbusonc #gynca https://t.co/2Hc0yAl1az
-
-
Mashup Score: 0OncLive News Network: On Location at ESMO 2020 - 4 year(s) ago
OncLive® will once again be LIVE with OncLive News Network: On Location at the 2020 ESMO Virtual Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the virtual conference.Register NowAlready Registered?Event Date *First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were…
Source: studio.mjhassoc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
TONIGHT AT 5 PM EST: Join our first virtual #OncLiveOnLocation at #ESMO20! @ginacolumbusonc speaks with Dr. Robert Coleman, of @TheUSONetwork, on key data in gynecologic cancers. Register for exclusive access: https://t.co/rpOheBInKg @myESMO #gynca https://t.co/kef8Z9xp1i
-
-
Mashup Score: 1FDA Approves Expanded Use of CINtec PLUS Cytology Test to Prevent Cervical Cancer in HPV+ Women - 4 year(s) ago
The FDA has approved the expanded use of the CINtec PLUS Cytology assay for women who undergo cervical cancer screening and test positive for high-risk types of human papillomavirus.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#FDA Approves Expanded Use of CINtec PLUS Cytology Test to Prevent Cervical Cancer in HPV+ Women @US_FDA #gynca #cxca https://t.co/z1kSEFTMn1
-
-
Mashup Score: 2
The first patient has been enrolled on the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The first patient has been enrolled on the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers. @ErikaHamilton9 @SarahCannonDocs #gynca https://t.co/5j8wgJYs4D
-
-
Mashup Score: 0
The first patient has been enrolled on the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@ErikaHamilton9, of @SarahCannonDocs, discusses the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers. #gynca https://t.co/9h7RfQtINk https://t.co/aLUu2RiEsl
-
-
Mashup Score: 0
The first patient has been enrolled on the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Lucitanib/Nivolumab Combo Enters Phase 2 Evaluation for Gynecologic Cancers @ErikaHamilton9 @SarahCannonDocs #gynca https://t.co/7F1djNFKwP
-
Maintenance PARP Yields Impressive PFS Benefit in Recurrent, Platinum-Sensitive Ovarian Cancer @uc_health #ovca #gynca #PARPi https://t.co/tA84oRUeZE